Sugi Predict

Sugi Predict / Compounds / SCHEMBL20182988

SCHEMBL20182988

SCHEMBL20182988

C[C@@H]1C=C(B2OC(C)(C)C(C)(C)O2)C[C@H](C)N1C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 2/20 0.38
▸ CHRM2 P08172 1/20 0.35
▸ CHRM1 P11229 1/20 0.35
▸ CHRM3 P20309 1/20 0.35
▸ ABCB1 P08183 1/20 0.32
▸ AAK1 Q2M2I8 1/20 0.32
▸ PREP P48147 1/20 0.32
▸ P2RX7 Q99572 1/20 0.31
▸ KDM1A O60341 1/20 0.31
▸ HSD11B1 P28845 1/20 0.31
▸ BUB1 O43683 1/20 0.31
▸ EED O75530 1/20 0.31
▸ RBBP4 Q09028 1/20 0.31
▸ SUZ12 Q15022 1/20 0.31
▸ EZH2 Q15910 1/20 0.31
▸ USP2 O75604 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ MAPK1 P28482 2/20 0.30
▸ BACE1 P56817 1/20 0.30
▸ BACE2 Q9Y5Z0 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19935894 1.00 USP30 (0.38) USP30CHRM2CHRM1CHRM3ABCB1
SCHEMBL19935895 1.00 USP30 (0.38) USP30CHRM2CHRM1CHRM3ABCB1
SCHEMBL4887916 1.00 USP30 (0.38) USP30CHRM2CHRM1CHRM3ABCB1
SCHEMBL25172608 0.82 P2RX7 (0.35) P2RX7MAPK1
SCHEMBL28381934 0.82 P2RX7 (0.35) P2RX7MAPK1
SCHEMBL12543898 0.82 P2RX7 (0.35) P2RX7MAPK1
SCHEMBL19078451 0.82 USP30 (0.38) USP30AAK1P2RX7BUB1USP2
SCHEMBL12461395 0.80 USP30 (0.39) USP30P2RX7HSD11B1USP2SMN1; SMN2
SCHEMBL21340355 0.80 USP30 (0.39) USP30P2RX7HSD11B1USP2SMN1; SMN2
SCHEMBL16272001 0.80 USP30 (0.39) USP30P2RX7HSD11B1USP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230142338-A1 THIOPHENYL DERIVATIVES USEFUL FOR MODULATING NUCLEIC ACID SPLICING REMIX THERAPEUTICS INC. 2023-05-11 — — US disclosed
US-20230142338-A1 THIOPHENYL DERIVATIVES USEFUL FOR MODULATING NUCLEIC ACID SPLICING REMIX THERAPEUTICS INC. 2023-05-11 — — US disclosed
EP-4110775-A1 THIOPHENYL DERIVATIVES USEFUL FOR MODULATING NUCLEIC ACID SPLICING Remix Therapeutics Inc. (US) 2023-01-04 — — EP disclosed
CN-115043821-A Aminopyrimidines as ALK inhibitors 密歇根大学董事会 2022-09-13 — — CN disclosed
EP-4001273-A2 AMINOPYRIMIDINES AS ALK INHIBITORS The Regents Of The University Of Michigan (US) 2022-05-25 — — EP disclosed
CN-109715620-B Aminopyrimidines as ALK inhibitors 密歇根大学董事会 2022-05-06 — — CN disclosed
US-11110090-B2 Aminopyrimidines as ALK inhibitors THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2021-09-07 — — US disclosed
US-20200330464-A1 AMINOPYRIMIDINES AS ALK INHIBITORS UNIV MICHIGAN REGENTS (US) 2020-10-22 — — US disclosed
US-10781208-B2 5,6-dihydro-11H-indolo[2,3-B]quinolin-11-ones as alk inhibitors THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2020-09-22 — — US disclosed
US-10781208-B2 5,6-dihydro-11H-indolo[2,3-B]quinolin-11-ones as alk inhibitors THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2020-09-22 — — US disclosed
US-10709705-B2 Aminopyrimidines as ALK inhibitors THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2020-07-14 — — US disclosed
US-20190315741-A1 5,6-DIHYDRO-11H-INDOLO[2,3-B]QUINOLIN-11-ONES AS ALK INHIBITORS UNIV MICHIGAN REGENTS (US) 2019-10-17 — — US disclosed
US-20190315741-A1 5,6-DIHYDRO-11H-INDOLO[2,3-B]QUINOLIN-11-ONES AS ALK INHIBITORS UNIV MICHIGAN REGENTS (US) 2019-10-17 — — US disclosed
US-20190175595-A1 AMINOPYRIMIDINES AS ALK INHIBITORS UNIV MICHIGAN REGENTS (US) 2019-06-13 — — US disclosed
WO-2018094134-A1 5,6-DIHYDRO-11H-INDOLO[2,3-B]QUINOLIN-11-ONES AS ALK INHIBITORS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2018-05-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190315741-A1 5,6-DIHYDRO-11H-INDOLO[2,3-B]QUINOLIN-11-ONES AS ALK INHIBITORS ALK, KRAS, ABL1 USP30 2937/4885CHRM2 337/4885CHRM1 462/4885
US-20200330464-A1 AMINOPYRIMIDINES AS ALK INHIBITORS ALK, RET, BRAF USP30 3040/4885CHRM2 1053/4885CHRM1 1411/4885
US-11110090-B2 Aminopyrimidines as ALK inhibitors ALK, RET, BRAF USP30 3040/4885CHRM2 1053/4885CHRM1 1411/4885
US-10781208-B2 5,6-dihydro-11H-indolo[2,3-B]quinolin-11-ones as alk inhibitors ALK, KRAS, ABL1 USP30 2809/4885CHRM2 285/4885CHRM1 406/4885
US-20230142338-A1 THIOPHENYL DERIVATIVES USEFUL FOR MODULATING NUCLEIC ACID SPLICING SNRPA, NSUN3, NSUN2 USP30 3896/4885CHRM2 4882/4885CHRM1 4860/4885
US-20190175595-A1 AMINOPYRIMIDINES AS ALK INHIBITORS ALK, RET, BRAF USP30 3040/4885CHRM2 1053/4885CHRM1 1411/4885
US-10709705-B2 Aminopyrimidines as ALK inhibitors ALK, RET, BRAF USP30 3040/4885CHRM2 1053/4885CHRM1 1411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.